

# Index

## A

- ABCBI*, 130–131, 167
- Acamprosate, historical perspective, 4–5
- Acetylcholine esterase (AChE), 277–278
- N*-acetylcysteine (NAC), psychostimulant use, 6–7
- AChE. *See* Acetylcholine esterase
- ACTH. *See* Adrenocorticotrophic hormone
- ADHD. *See* Attention-deficit/hyperactivity disorder
- Adrenocorticotrophic hormone (ACTH), prenatal opioid exposure effects, 180
- AKT, 209
- Alcohol use disorder (AUD)
  - brain-derived neurotrophic factor modulation
    - alcohol effects on expression, 333–337
    - behavior regulation, 337–340
    - overview, 332–333
  - central amygdala and alcohol dependence
  - corticotrophin-releasing factor
    - behavior effects, 314–315
    - synaptic transmission effects, 315–316
  - disinhibition model of output, 319
  - GABAergic system
    - acute alcohol augmentation, 309–310
    - chronic alcohol effects, 310–312
    - overview, 309
  - glutamatergic transmission
    - acute alcohol effects, 312
    - chronic alcohol effects, 312–313
    - overview, 312
  - negative emotional circuitry, 308–309
  - neuropeptidergic systems, 313–314
  - nociceptin
    - behavior effects, 316–317
    - synaptic transmission effects, 317
  - oxytocin
    - behavior effects, 318–319
    - synaptic transmission effects, 319
  - fibroblast growth factor 2 modulation, 346–347
  - glial-derived neurotrophic factor modulation
    - alcohol effects on expression, 342–343
    - behavior regulation, 343–345
    - overview, 341–342
  - insulin-like growth factor 1 modulation
    - alcohol effects on expression, 350–351
    - behavior regulation, 351
    - overview, 350
  - midkine/PTN/ALK modulation
    - alcohol effects on expression, 347–348
    - behavior regulation, 348–349
    - overview, 347
  - overview, 307–308, 331–332
- ALK, alcohol use disorder modulation
  - alcohol effects on expression, 347–348
  - behavior regulation, 348–349
  - overview, 347
- AM251, 370, 386
- AMPA receptor
  - alcohol dependence glutamatergic transmission
    - acute alcohol effects, 312
    - chronic alcohol effects, 312–313
    - overview, 312
  - nucleus accumbens overview, 72–73
  - opioids
    - basolateral amygdala pathways, 229–230
    - conditioned reinforcement, 222
    - effects in ventral tegmental area dopamine neurons, 203–204, 206, 209–210
    - extinction and reinstatement, 223–224
    - hippocampal projections, 231
    - memory regulation, 226
    - nucleus accumbens, 231–232
    - prefrontal cortex pathways, 227–228
    - reward, 219
    - withdrawal and aversion, 221
  - psychostimulant-induced postsynaptic adaptations
    - in nucleus accumbens
      - cell-type and pathway specificity, 77–78
      - overview, 74–75
      - plasticity mechanisms, 75–77
      - silent synapses and synaptogenesis, 78–82
      - transient synaptic plasticity, 82–83
    - ventral tegmental area, 112, 114–119
- Amygdala. *See* Basolateral amygdala; Central amygdala
- Anandamide, 366–367, 373, 380
- Animal models
  - behavioral symptoms of addiction
    - drug seeking after extinction, 17–18
    - escalation of drug use, 12–14
    - exaggerated motivation for drugs, 16–17
    - extinction resistance, 15–16
    - neurocognitive deficits, 14–15
    - overview, 11–12
    - prospects for study, 22–23
    - punishment resistance, 20–22

## Index

- Animal models (*Continued*)  
    reward preference for drugs, 18–20  
    genetic vulnerability to opioid addiction  
    mouse models, 128–130  
    overview, 127–128  
    quantitative trait loci, 128  
    genome-wide association studies, 294–296  
    historical perspective, 2  
    neonatal opioid withdrawal syndrome, 169  
    nicotine dependence rodent models  
        administration routes, 290  
        overview, 289–290  
        reward, 290–291  
        withdrawal, 291  
    overview of substance use disorder models, 97–98
- Anterior cingulate, addiction neurocircuitry, 40
- Anxiety, nicotinic acetylcholine receptor regulation  
    in nicotine addiction, 277–278
- Appetite, nicotinic acetylcholine receptor regulation  
    in nicotine addiction, 279–280
- 2-Arachidonoylglycerol, 366–367, 373, 388–389
- Arch, 60
- Attention, nicotinic acetylcholine receptor regulation  
    in nicotine addiction, 278–279
- Attention-deficit/hyperactivity disorder (ADHD)  
    neonatal opioid withdrawal syndrome outcomes,  
        169, 177  
    stimulant abuse, 36
- AUD. *See* Alcohol use disorder
- B**
- Basolateral amygdala (BLA)  
    cannabinoids and synaptic plasticity, 387–388  
    nicotinic acetylcholine receptors, 278  
    opioids  
        reconsolidation, 223  
        reward pathways, 228–230  
    relapse neurobiology, 42, 45
- BBB. *See* Blood–brain barrier
- BDNF. *See* Brain-derived neurotrophic factor
- Bed nucleus of the stria terminalis (BNST), alcohol  
    use disorder role, 308, 314
- Behavioral symptoms of addiction. *See* Animal models
- BLA. *See* Basolateral amygdala
- Blood–brain barrier (BBB), opioid tolerance role, 262
- BNST. *See* Bed nucleus of the stria terminalis
- Brain-derived neurotrophic factor (BDNF)  
    alcohol use disorder modulation  
        alcohol effects on expression, 333–337  
        behavior regulation, 337–340  
        overview, 332–333  
    distribution in brain, 332  
    opioid tolerance role, 263  
    prenatal opioid exposure effects, 179  
    ventral tegmental area functions, 207–208
- Buprenorphine  
    effects on opioid choice, 146–147  
    historical perspective, 2–3
- Bupropion, historical perspective, 5–6
- C**
- CA1 synapse, cannabinoids and synaptic  
    plasticity, 384–386
- Calcitonin gene-related peptide (CGRP), 260
- Calcium-calmodulin kinase II (CaMKII), 75–76,  
    288, 371
- CaMKII. *See* Calcium-calmodulin kinase II
- Cannabinoid receptor  
    CB1, 39, 364–366, 368–371, 380–383, 385,  
        387–388  
    CB2, 373, 386  
    dopamine induction by cannabinoids, 364  
    dopamine neurons and cannabinoid effects  
        dopamine release, 369  
        mechanisms of dopamine release, 369–371  
        phasic firing, 364–365  
    endocannabinoid system  
        ligands, 380  
        negative reinforcement and aversion studies,  
            371–373  
    overview, 363–364  
    plasticity studies  
        basolateral amygdala, 387–388  
        dysregulation by exogenous cannabinoids,  
            383  
        hippocampus, 384–386  
        long-term plasticity, 381–383  
        nucleus accumbens, 383–384  
        short-term plasticity, 381  
        ventral tegmental area, 386–387  
    signaling disruption  
        cue-evoked dopamine release decrease,  
            365–366  
        dopamine neuron firing effects, 366,  
            368–369
- CCK. *See* Cholecystokinin
- CeA. *See* Central amygdala
- Central amygdala (CeA)  
    alcohol dependence  
        corticotrophin-releasing factor  
            behavior effects, 314–315  
            synaptic transmission effects, 315–316  
    disinhibition model of output, 319
- GABAergic system  
    acute alcohol augmentation, 309–310  
    chronic alcohol effects, 310–312  
    overview, 309
- glutamatergic transmission  
    acute alcohol effects, 312  
    chronic alcohol effects, 312–313

overview, 312  
negative emotional circuitry, 308–309  
neuropeptidergic systems, 313–314  
nociceptin  
    behavior effects, 316–317  
    synaptic transmission effects, 317  
oxytocin  
    behavior effects, 318–319  
    synaptic transmission effects, 319  
opioid reward pathways, 229–230  
CGRP. *See* Calcitonin gene-related peptide  
*CHNRA3*, 274  
*CHNRA5*, 274, 294–295  
*CHNRAB4*, 274  
Cholecystikinin (CCK), 254  
Chromatin structure. *See* Epigenetics, addiction  
Clonidine, neonatal opioid withdrawal syndrome management, 166  
Cocaine, vaccine, 7  
Cognition, nicotine addiction studies, 292–293  
Corticotrophin-releasing factor (CRF)  
    alcohol use disorder  
        behavior effects, 314–315  
        overview of role, 308–309  
        synaptic transmission effects, 315–316  
    binding protein, 315  
    receptor therapeutic targeting, 151  
    relapse neurobiology, 45  
CREB, 80–81, 103–105, 189, 223, 288  
CRF. *See* Corticotrophin-releasing factor  
*CRHBP*, 131, 315  
CRISPR, 250  
*CX3CL1*, 260  
*CXCL12*, 260  
*CXCR3*, 260  
*CYP2B6*, 167  
*CYP2D6*, 167

**D**

$\Delta$ FosB, 104  
Depression  
    neonatal opioid withdrawal syndrome risks, 169  
    nicotinic acetylcholine receptor regulation in  
        nicotine addiction, 277–278  
*Diagnostic and Statistical Manual of Mental Disorders*,  
    5th Edition (DSM5), criteria for  
        substance use disorder, 12–13  
DNA methylation. *See* Epigenetics, addiction  
Dopaminergic pathway. *See also specific brain regions*  
    addiction neurocircuitry, 37–39  
    cocaine self-administration studies, 371  
    dopamine receptor antagonist therapy, 6  
    neuron activity, 362–363  
    relapse neurobiology, 42–43  
Dorsal striatum, addiction neurocircuitry, 40

*DRD2*  
    neonatal opioid withdrawal syndrome genetic  
        susceptibility, 167  
    nicotine addiction polymorphisms  
        mouse models, 295–296  
        smokers, 295  
DSM5. *See Diagnostic and Statistical Manual of Mental Disorders*, 5th Edition

**E**

EAAT1, 220  
EAAT2, 220  
EAAT3, 220  
Endocannabinoid system. *See* Cannabinoid receptor  
Epidemiology, drug use, 35–36  
Epigenetics, addiction  
    animal models, 97–98  
    chromatin structure regulation, 92–93, 101–102  
    DNA methylation, 94–95, 102–103  
    histone modifications, 93–94, 98–101  
    neonatal opioid withdrawal syndrome, 167  
    neurocircuitry, 96  
    noncoding RNA, 95, 103  
    preconception opioid effects on offspring, 185–186  
    prospects for study, 105–106  
    transcription factors, 95–96, 103–105

**F**

Fagerström Test of Nicotine Dependence (FTND), 289  
Fagerström Tolerance Questionnaire (FTQ), 289  
Fentanyl, vaccine, 144–145  
FGF2. *See* Fibroblast growth factor 2  
Fibroblast growth factor 2 (FGF2), alcohol use disorder  
    modulation, 346–347  
Follicle-stimulating hormone (FSH), 183  
FSH. *See* Follicle-stimulating hormone  
FTND. *See* Fagerström Test of Nicotine Dependence  
FTQ. *See* Fagerström Tolerance Questionnaire

**G**

GABA receptor  
    alcohol dependence GABAergic system  
        acute alcohol augmentation, 309–310  
        chronic alcohol effects, 310–312  
        overview, 309  
    CB1 receptors on neurons, 371  
    opioid effects in ventral tegmental area dopamine  
        neurons, 205–206  
    relapse neurobiology, 43–44  
    single-cell imaging, 65–66  
    ventral tegmental area, 233–234  
GDNF. *See* Glial-derived neurotrophic factor  
GIRK, 206

## Index

- Glial-derived neurotrophic factor (GDNF)  
  alcohol use disorder modulation  
    alcohol effects on expression, 342–343  
    behavior regulation, 343–345  
    overview, 341–342  
  functional overview, 341–342
- GLP-1. *See* Glucagon-like peptide 1
- GLT-1. *See* Glutamate transporter 1
- Glucagon-like peptide 1 (GLP-1), 254, 275–276
- Glutamate transporter 1 (GLT-1), 73, 220, 225–226
- GRK, 262
- Gut microbiota  
  dysbiosis impact, 248  
  gut–brain axis  
    communication pathways  
      gut hormones, 254–255  
      immune mediators, 253–254  
      microbial metabolites, 251–253  
      vagus nerve, 255–256  
    opioid effects  
      comorbidities, 256–257  
      dysbiosis and pathogen virulence, 257–258  
      mechanisms, 258–259  
    opioid tolerance mechanisms  
      blood–brain barrier role, 262  
      microbiota studies, 263–265  
      neuroinflammation, 260–261  
      overview, 259–260  
      signaling pathways, 261–262  
      Toll-like receptors, 261  
    overview, 247–249  
  research tools, 250–251
- H**
- Habenula, aversion and withdrawal circuitry, 273–276
- Hippocampus  
  addiction neurocircuitry, 72  
  cannabinoids and synaptic plasticity, 384–386  
  nicotinic acetylcholine receptors, 278  
  opioid reward projections, 231  
  relapse neurobiology, 42
- Histones. *See* Epigenetics, addiction
- I**
- IGF-1. *See* Insulin-like growth factor 1
- Impulsivity, 293–294
- Incentive sensitization, theory of addiction, 36
- Insulin-like growth factor 1 (IGF-1), alcohol use disorder modulation  
  alcohol effects on expression, 350–351  
  behavior regulation, 351  
  overview, 350
- Interpeduncular nucleus (IPN), nicotine aversion and withdrawal circuitry, 273–276
- IPN. *See* Interpeduncular nucleus
- IRS2, 209
- K**
- KCNAB2, 206
- L**
- LC. *See* Locus coeruleus
- LH. *See* Luteinizing hormone
- Locus coeruleus (LC), 189
- Long-term depression (LTD), cannabinoid effects, 380, 382–384, 387
- Long-term potentiation (LTP), cannabinoid effects, 379–382, 384–386
- LTD. *See* Long-term depression
- LTP. *See* Long-term potentiation
- Luteinizing hormone (LH), 183
- M**
- MDK. *See* Midkine
- Methadone  
  effects on opioid choice, 147–148  
  genetics of maintenance therapy, 130–131  
  historical perspective, 2–3  
  neonatal opioid withdrawal syndrome management, 165
- Methocinnamox, MOR antagonism, 145
- Microbiota. *See* Gut microbiota
- Midkine (MDK), alcohol use disorder modulation  
  alcohol effects on expression, 347–348  
  behavior regulation, 348–349  
  overview, 347
- MK-212, 150
- MMP-9, 226
- MOR. *See* Opioid receptor
- MyD88, 261
- N**
- NAC. *See* *N*-acetylcysteine
- Nac. *See* Nucleus accumbens
- nAChR. *See* Nicotinic acetylcholine receptor
- Naloxone, 3, 145
- Naltrexone  
  historical perspective, 3–4  
  infant exposure effects, 166  
  MOR antagonism, 145
- NASH. *See* Nonalcoholic steatohepatitis
- NDSS. *See* Nicotine Dependence Syndrome Scale
- Neonatal opioid withdrawal syndrome (NOWS)  
  animal models, 169  
  assessment, 165  
  clinical presentation, 164, 176–177  
  diagnosis, 165

- epidemiology, 163–164
  - epigenetics, 167
  - genetic susceptibility, 167
  - longitudinal studies, 167–169
  - prospects for study, 169–170
  - treatment, 165–166
  - Neuropeptide Y (NPY), 254
  - NGFB*, 131
  - Nicotine addiction
    - DRD2* polymorphisms
      - mouse models, 295–296
      - smokers, 295
    - health impact, 277
    - imaging studies, 292
    - impulsivity, 293–294
    - instruments for dependence measurement, 289
    - negative affect and cognition, 292–293
    - nicotine neurochemistry, 288
    - nicotinic acetylcholine receptors
      - aversion and withdrawal circuitry, 273–276
      - behavior regulation
        - anxiety and depression, 277–278
        - appetite, 279–280
        - attention, 278–279
        - overview, 276–277
      - polymorphisms
        - mouse models, 294–295
        - smokers, 294
      - reinforcement receptor subtypes, 271–273
    - OPRM1* polymorphisms
      - mouse models, 296–297
      - smokers, 296
    - rodent models
      - administration routes, 290
      - overview, 289–290
      - reward, 290–291
      - withdrawal, 291
    - treatment, 288
  - Nicotine Dependence Syndrome Scale (NDSS), 289
  - Nicotine replacement therapy, historical perspective, 5–6
  - Nicotinic acetylcholine receptor (nAChR)
    - CB1 receptors on neurons, 371
    - dopamine release and cannabinoids, 371
  - nicotine addiction
    - aversion and withdrawal circuitry, 273–276
    - behavior regulation
      - anxiety and depression, 277–278
      - appetite, 279–280
      - attention, 278–279
      - overview, 276–277
    - polymorphisms
      - mouse models, 294–295
      - smokers, 294
    - reinforcement receptors, 272–273
    - subtypes, 271–272, 288–289
  - NLRP3, 261
  - NMDA receptor
    - alcohol dependence glutamatergic transmission
      - acute alcohol effects, 312
      - chronic alcohol effects, 312–313
      - overview, 312
    - nucleus accumbens, 76–77, 79, 81
  - opioids
    - basolateral amygdala pathways, 229–230
    - conditioned reinforcement, 222
    - extinction and reinstatement, 224
    - hippocampal projections, 231
    - nucleus accumbens, 231–232
    - prefrontal cortex pathways, 227–228
    - reward, 218–219
    - ventral tegmental area dopamine neuron effects, 203–204, 206, 209–210, 233–234
    - withdrawal and aversion, 220
    - ventral tegmental area and drug-evoked synaptic plasticity, 112–119
  - Nociceptin, alcohol dependence
    - behavior effects, 316–317
    - synaptic transmission effects, 317
  - Nociceptin opioid peptide (NOP), 154, 316–317
  - Nonalcoholic steatohepatitis (NASH), 263
  - NOP. *See* Nociceptin opioid peptide
  - NOWS. *See* Neonatal opioid withdrawal syndrome
  - NPY. *See* Neuropeptide Y
  - NST. *See* Nucleus of the solitary tract
  - Nucleus accumbens (NAc)
    - addiction neurocircuitry, 37–39, 71, 73, 150
    - alcohol use disorder, 308
    - cannabinoids and synaptic plasticity, 383–384
    - dopamine and endocannabinoids in negative reinforcement and aversion studies, 372–373
    - glutamatergic transmission, 72–73
    - nicotine addiction and nicotinic acetylcholine receptors, 272
    - opioid reward projections, 231–232
    - optogenetic studies, 62
    - psychostimulant-induced adaptations in glutamatergic transmission
      - postsynaptic adaptations
        - AMPA receptors, 74–77
        - cell-type and pathway specificity, 77–78
        - silent synapses and synaptogenesis, 78–82
        - transient synaptic plasticity, 82–83
      - presynaptic adaptations, 73–74
    - relapse neurobiology, 42–45
  - Nucleus of the solitary tract (NST), nicotinic acetylcholine receptors, 275
- O**
- OFC. *See* Orbitofrontal cortex
  - Opioid

## Index

- Opioid (*Continued*)
- conditioned reinforcement, 221–222
  - extinction and reinstatement
    - glutamate transporters, 224–226
    - ionotropic glutamate receptors, 223–224
    - metabotropic receptors, 224–226
  - gut–brain axis
  - opioid effects
    - comorbidities, 256–257
    - dysbiosis and pathogen virulence, 257–258
    - mechanisms, 258–259
  - tolerance mechanisms
    - blood–brain barrier role, 262
    - microbiota studies, 263–265
    - neuroinflammation, 260–261
    - overview, 259–260
    - signaling pathways, 261–262
    - Toll-like receptors, 261
  - memory processes, 222–223, 226–227
  - plasticity induction in ventral tegmental area
    - dopamine neurons
  - acute effects
    - overview, 203
    - synaptic plasticity, 203–206
  - chronic effects
    - cellular plasticity, 207–208
    - structural plasticity, 208–210
    - synaptic plasticity, 206–207
  - heterogeneity of responses, 210–211
  - prospects for study, 211–212
  - reconsolidation, 223
  - reward
    - amygdala pathways, 228–230
    - conditioned, 218
    - glutamate receptors
      - ionotropic receptors, 218–219
      - metabotropic receptors, 219–220
    - glutamate transporters, 220
    - hippocampal projections, 231
    - nucleus accumbens projections, 231–232
    - paraventricular nucleus of the thalamus
      - pathways, 230–231
    - prefrontal pathways, 227–228
    - primary, 218
    - ventral tegmental area projections, 232–233
  - withdrawal and aversion, 220–221
- Opioid receptor
- genetic vulnerability to opioid addiction
    - animal models
      - mouse models, 128–130
      - overview, 127–128
      - quantitative trait loci, 128
    - methadone maintenance therapy, 130–131
    - neonatal opioid withdrawal syndrome, 167
    - OPRM1* A118G
      - associations with diverse diseases, 126–127
      - overview, 123–125, 127
      - prospects for study, 131–132
  - KOR, 151
  - MOR
    - activation, 141–142
    - agonists, 146–149
    - antagonists, 145–146
    - methadone targeting, 130
  - nicotine addiction and *OPRM1* polymorphisms
  - mouse models, 296–297
  - smokers, 296
- Opioid use disorder (OUD)
- medication effects on opioid choice
  - MOR
    - activation, 141–142
    - agonists, 146–149
    - antagonists, 145–146
  - opioid cost and availability, 152–153
  - opioid distribution targeting, 142, 144
  - overview of studies, 141–143
  - postreceptor effects and negative reinforcement, 150–151
  - postreceptor toxic effects, 151–152
  - prospects for study, 153–155
- overview, 137–138
- preconception effects on offspring
- maternal lineage, 182–183
  - paternal lineage
    - cognition, 188
    - endogenous opioid system impact, 184
    - germline reprogramming, 185–186
    - limitations of studies, 189–190
    - neural mechanisms, 188–189
    - reproductive and sexual function, 183–184
    - reward processing and pain sensitivity alterations, 186–188
- prenatal exposure. *See also* Neonatal opioid withdrawal syndrome
- animal studies
    - early developmental changes, 178–179
    - endogenous opioid system impact, 179–180
    - long-term consequences, 180–181
    - overview, 178
  - immediate consequences, 176–177
  - long-term consequences, 177–178
  - maternal characteristics, 176
  - mechanisms of developmental effects, 181–182
  - treatment medication development strategies, 138–141
- OPRM1*. *See* Opioid receptor
- Optogenetics, motivation circuit studies
- opsins, 60–61
  - overview, 60–61
  - slice electrophysiology studies, 61–62

- Orbitofrontal cortex (OFC)  
addiction neurocircuitry, 37, 40–41  
relapse neurobiology, 42  
single-cell imaging, 65
- OUD. *See* Opioid use disorder
- Oxytocin, alcohol dependence  
behavior effects, 318–319  
synaptic transmission effects, 319
- P**
- p38 MAPK, 257
- Paraventricular nucleus of the thalamus (PVT)  
addiction neurocircuitry, 72–73  
opioid reward pathways, 230–231
- PDYN*, 184
- PENK*, 184
- PFC. *See* Prefrontal cortex
- Phenobarbital, neonatal opioid withdrawal  
syndrome management, 166
- Phospholipase C (PLC), 219
- PKC. *See* Protein kinase C
- PLC. *See* Phospholipase C
- Pleiotrophin (PTN), alcohol use disorder modulation  
alcohol effects on expression, 347–348  
behavior regulation, 348–349  
overview, 347
- POMC. *See* Proopiomelanocortin
- Posttraumatic stress disorder (PTSD), 255
- Prefrontal cortex (PFC)  
addiction neurocircuitry, 37, 40–41  
growth factors in alcohol use disorder, 332, 334, 340, 348  
nicotinic acetylcholine receptors, 278, 292–293  
opioid reward pathways, 227–228  
relapse neurobiology, 42–44
- Proopiomelanocortin (POMC), 184, 279
- Protein kinase C (PKC), 288
- PSD-95, 81
- PTN. *See* Pleiotrophin
- PTSD. *See* Posttraumatic stress disorder
- PVT. *See* Paraventricular nucleus of the thalamus
- PYY, 254
- R**
- RACK1, 337, 339
- Relapse, neurobiology, 41–46
- RET, 341
- S**
- SGK1, 207–208
- Single-cell imaging, motivation circuit studies, 64–66
- Single-cell sequencing, motivation circuit studies, 62–64
- SLC6A3, 295
- Stages, drug addiction, 37
- T**
- TCF7L2, 276
- THC. *See* Cannabinoid receptor
- TLR2, 261, 265
- TLR4, 260–262, 265
- V**
- Vagus nerve, gut–brain axis, 255–256
- Varenicline, historical perspective, 5–6
- Ventral tegmental area (VTA)  
addiction neurocircuitry, 37–39, 150  
cannabinoids  
dopamine release, 364, 369  
synaptic plasticity studies, 386–387  
drug-evoked synaptic plasticity  
altered circuit function, 117–118  
behavioral repercussions, 118–119  
mesolimbic dopamine in induction, 112–114  
overview, 111–112  
receptor expression mechanism, 114–115  
reversal, 117  
synaptic function, 115–117  
growth factors in alcohol use disorder, 332, 341–345, 352  
neuron complexity, 202–203  
nicotine addiction  
negative affect and cognition, 292  
nicotinic acetylcholine receptors, 272–273  
opioid-induced plasticity in dopamine neurons  
acute effects  
overview, 203  
synaptic plasticity, 203–206  
chronic effects  
cellular plasticity, 207–208  
structural plasticity, 208–210  
synaptic plasticity, 206–207  
heterogeneity of responses, 210–211  
prospects for study, 211–212  
opioid reward projections, 232–233  
optogenetic studies, 62  
relapse neurobiology, 43–45  
single-cell imaging, 65
- VTA. *See* Ventral tegmental area
- W**
- Wisconsin Inventory of Smoking Dependence  
Motives (WISDM), 289
- WISDM. *See* Wisconsin Inventory of Smoking  
Dependence Motives